KBC Group NV increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 12.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,167 shares of the medical equipment provider’s stock after buying an additional 2,157 shares during the period. KBC Group NV’s holdings in Zimmer Biomet Holdings were worth $2,589,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. Enterprise Financial Services Corp raised its position in Zimmer Biomet Holdings by 0.3% in the second quarter. Enterprise Financial Services Corp now owns 2,646 shares of the medical equipment provider’s stock worth $340,000 after buying an additional 9 shares in the last quarter. Sandy Spring Bank raised its stake in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 20 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares in the last quarter. Cleararc Capital Inc. raised its stake in shares of Zimmer Biomet Holdings by 0.5% in the first quarter. Cleararc Capital Inc. now owns 4,897 shares of the medical equipment provider’s stock worth $598,000 after buying an additional 25 shares in the last quarter. Finally, Palladium Partners LLC raised its stake in shares of Zimmer Biomet Holdings by 1.7% in the second quarter. Palladium Partners LLC now owns 2,501 shares of the medical equipment provider’s stock worth $321,000 after buying an additional 41 shares in the last quarter. 82.84% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at 113.19 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $95.63 and a 12 month high of $133.49. The company’s 50 day moving average price is $120.75 and its 200 day moving average price is $120.97. The firm has a market capitalization of $22.89 billion, a P/E ratio of 32.24 and a beta of 1.20.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. The business had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The company’s quarterly revenue was up 1.1% on a year-over-year basis. During the same period last year, the firm earned $2.02 earnings per share. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date of this dividend is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio is currently 27.59%.

ILLEGAL ACTIVITY WARNING: “KBC Group NV Raises Stake in Zimmer Biomet Holdings, Inc. (ZBH)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/27/kbc-group-nv-raises-stake-in-zimmer-biomet-holdings-inc-zbh.html.

A number of equities research analysts have weighed in on ZBH shares. Goldman Sachs Group, Inc. (The) started coverage on Zimmer Biomet Holdings in a report on Tuesday, May 16th. They issued a “sell” rating and a $92.00 price objective on the stock. Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 8th. Morgan Stanley lifted their price objective on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, July 17th. Oppenheimer Holdings, Inc. set a $137.00 price objective on Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Monday, August 14th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet Holdings in a report on Tuesday, July 11th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet Holdings presently has a consensus rating of “Hold” and a consensus price target of $136.75.

In related news, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sang Yi sold 17,731 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by insiders.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.